Data from clinical trials revealed that PD-L1 expression measured with tumour proportion score (TPS) or combined pathological score (CPS) is a potential biomarker to guide the selection of patients who could benefit from ICPIs [6]. The gene discussed is CD274; the disease is neoplasm.